ABCL vs ARQT: stock comparison and AI forecast
Abcellera Biologics Inc. (ABCL) and Arcutis Biotherapeutics, Inc. (ARQT) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ABCL Abcellera Biologics Inc.
- Market Cap
- $3.73B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
ARQT Arcutis Biotherapeutics, Inc.
- Price
- $32.00 +36.6% · 6M
- Market Cap
- $4.02B
- P/E Ratio
- 290.9x
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- ABCL and ARQT have similar market capitalizations ($3.73B and $4.02B).
- ARQT carries 1.21 times debt per unit of equity, against 0.46 times for ABCL.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ABCL | ARQT |
|---|---|---|
| Market Cap | $3.73B | $4.02B |
| P/E Ratio | – | 290.91x |
| P/B Ratio | 4.17x | 18.23x |
| EPS | $-0.55 | $0.11 |
| Book Value/Share | $2.92 | $1.75 |
| Revenue/Share | $0.23 | $3.69 |
| FCF/Share | $-0.39 | $0.31 |
Profitability & Margins
| Metric | ABCL | ARQT |
|---|---|---|
| ROE | -18.4% | – |
| ROA | -12.6% | – |
| ROIC | -17.9% | 10.4% |
| Gross Margin | – | 91.1% |
| Operating Margin | -319.8% | 7.4% |
| Net Margin | -233.9% | – |
| EBT Margin | -279.5% | 6.8% |
| Tax Rate | 16.3% | 2.5% |
Financial Health
| Metric | ABCL | ARQT |
|---|---|---|
| Current Ratio | 12.77x | 2.92x |
| Quick Ratio | 12.63x | 2.67x |
| D/E Ratio | 0.46x | 1.21x |
| Financial Leverage | 1.46x | 2.21x |
| Interest Coverage | – | 4.2x |
| Working Capital | $626M | $307M |
Cash Flow
| Metric | ABCL | ARQT |
|---|---|---|
| Operating Cash Flow | -$95M | $39M |
| Free Cash Flow | -$120M | $39M |
| Capital Spending | -$25M | -$160K |
| FCF/Sales | -170.0% | 8.4% |
| CapEx/Sales | 35.1% | 0.0% |
Operational Efficiency
| Metric | ABCL | ARQT |
|---|---|---|
| Asset Turnover | 0.05x | 0.95x |
| Receivables Turnover | 1.8x | 3.0x |
| Inventory Turnover | – | 1.1x |
| Fixed Assets Turnover | – | 532.1x |
| Days Sales Outstanding | 199 days | 122 days |
| Days Inventory | – | 345 days |
| Payables Period | – | 59 days |
| Cash Conversion Cycle | – | 409 days |
Income Statement
| Metric | ABCL | ARQT |
|---|---|---|
| Total Revenue | $70M | $464M |
| Operating Income | -$225M | $34M |
| Net Income | -$165M | – |
| R&D Expense | $198M | $91M |
| SG&A Expense | $173M | $298M |
| Cost of Goods Sold | – | $41M |
Dividend & Shareholder Information
| Metric | ABCL | ARQT |
|---|---|---|
| Shares Outstanding | 307M | 126M |
ABCL vs ARQT: stock comparison and AI forecast
Which is bigger, ABCL or ARQT?
ABCL and ARQT have similar market capitalizations ($3.73B and $4.02B).
Which one does Intratio's AI model rank higher, ABCL or ARQT?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.